Verastem (VSTM) Company Report

Verastem is focused on the launch of avutometinib for low-grade serous ovarian cancer, noting that patients are switching to their drug upon progression or intolerability from current therapies.
2026 is anticipated to be a critical year for the company, balancing continued launch momentum with accelerated development of their G12D inhibitor.
Initial results for the primary endpoint (PFS) from the RAMP 301 study are expected in the second half of 2027.
Their G12D inhibitor has demonstrated strong efficacy in collaborator GenFleet's trials, with a 69% response rate in lung and 58% in second-line pancreatic at the recommended phase II dose, positioning it as potentially best-in-class.
The company is actively pursuing combination therapies for its G12D inhibitor, including cetuximab for second-line colorectal and chemo/chemo-IO for lung, with a strategic focus on achieving frontline approval.

3 days ago

Transcript

Verastem Provides Update on Avutometinib Launch and G12D Inhibitor Program

VSTM

Product Launch

New Projects/Investments

Guidance Update

Verastem is advancing its small molecule pipeline targeting the RAS pathway, with avutometinib launched for low-grade serous ovarian cancer and a G12D inhibitor in development. The company expects 2026 to be a pivotal year for both the continued launch momentum and the acceleration of the G12D development program.
The launch of avutometinib is seeing an expected NCCN guidance update in early 2026, which is anticipated to influence the launch trajectory. The RAMP 301 trial, after an interim analysis, added 29 patients to both wild type and mutant arms, with initial results (PFS) expected in the second half of 2027.
Verastem's G12D inhibitor, through its collaborator GenFleet, has demonstrated high efficacy, reporting a 69% response rate in lung cancer and a 58% response rate in second-line pancreatic cancer at the recommended phase 2 dose. Verastem is implementing trial design elements like prophylactic antiemetics to address tolerability concerns observed in GenFleet's data.
The company is actively developing combination therapies for its G12D inhibitor, including a Cetuximab combination for second-line colorectal cancer and exploring chemo/immuno-oncology combinations for lung cancer, with a strategic focus on achieving frontline approvals.

3 days ago

Transcript

Verastem Provides Updates on Avutometinib Launch and KRAS G12D Program

VSTM

Product Launch

New Projects/Investments

Guidance Update

Verastem is actively managing the launch of avutometinib for low-grade serous ovarian cancer, with expectations for continued progress in 2026 and efforts to tighten market consensus. The company anticipates an update to NCCN guidelines sometime after the first of the year, which could impact launch trajectory.
The RAMP 301 trial for avutometinib, which added 29 patients based on IDMC recommendation, is expected to have initial results (PFS) in the second half of 2027.
Verastem's G12D inhibitor shows promising efficacy, with collaborator GenFleet reporting a 69% response rate in lung and a 58% response rate in second-line pancreatic patients at the recommended phase two dose, which is considered best-in-class.
For 2026, Verastem plans to maintain momentum for the avutometinib launch and accelerate the development program for its G12D asset, including a Cetuximab combination for colorectal cancer and chemo combinations for lung cancer.

3 days ago

Transcript

Verastem Discusses 2025 Launch Dynamics and G12D Inhibitor Progress

VSTM

Product Launch

New Projects/Investments

Revenue Acceleration/Inflection

Verastem's launched drug for low-grade serous ovarian cancer is performing well, with the company expecting to continue delivering quarter by quarter in 2026. The market dynamic involves patients switching from current therapies due to disease progression or intolerability, and Verastem aims to be their first choice.
The company's G12D inhibitor shows "best in class" clinical data from China, with a 69% response rate in lung cancer and a 58% response rate in second-line pancreatic cancer.
Verastem is actively developing its G12D program, including a cetuximab combination for second-line colorectal cancer and chemo combinations for lung cancer, with a strategic focus on achieving frontline approval.
The Ramp 301 trial, related to the ovarian cancer drug, added 29 patients based on an IDMC recommendation, indicating positive progress, with initial results (PFS) anticipated around 2027.

3 days ago

Transcript

Verastem Updates on Commercial Product Performance, G12D Program, and Clinical Milestones

VSTM

Product Launch

New Projects/Investments

Revenue Acceleration/Inflection

Verastem's commercial product, avutometinib and defactinib, approved for low-grade serous ovarian cancer, has beaten consensus by approximately 100% since its launch earlier this year and is expected to be self-sustaining within the next two to three quarters.
The company's G12D inhibitor, licensed from GenFleet, has shown promising results, with GenFleet reporting a 69% response rate in G12D non-small cell lung cancer and a 58% response rate in second-line pancreatic cancer; the US Phase 1 study has completed initial dose cohorts with no dose-limiting toxicities.
An Independent Data Monitoring Committee recommended adding 29 patients to the confirmatory Phase 3 RAMP301 study for low-grade serous ovarian cancer, a decision that does not alter the regulatory timeline, with final analysis for PFS still anticipated in H2 2027.
Key upcoming milestones include additional data from the frontline pancreatic study and the G12D Phase 1 study (including combinations) in the first half of next year.

Nov 19, 2025, 2:30 PM

Transcript

Verastem Provides Updates on Commercial Launch, G12D Program, and Clinical Trials

VSTM

Product Launch

New Projects/Investments

Revenue Acceleration/Inflection

Verastem's commercial product, avutometinib and defactinib, for low-grade serous ovarian cancer, has exceeded consensus by approximately 100% in its initial launch quarters.
The G12D inhibitor program, licensed from GenFleet, has demonstrated unprecedented efficacy in China, with a 69% response rate in G12D non-small-cell lung cancer and a 58% response rate in second-line pancreatic cancer. The U.S. Phase 1 study has initiated combination studies and shown no dose-limiting toxicities.
An interim analysis for the frontline metastatic pancreatic cancer study reported an 83% confirmed response rate, significantly surpassing the standard of care's 30%.
The confirmatory Phase 3 RAMP301 study for low-grade serous ovarian cancer will complete accrual in Q1 2025, with final analysis expected in H2 2027, following a recommendation to enroll 29 additional patients.

Nov 19, 2025, 2:30 PM

Transcript

Verastem Provides Update on Commercial Launch and Pipeline Progress

VSTM

Product Launch

New Projects/Investments

Revenue Acceleration/Inflection

Verastem's commercial product, avutometinib and defactinib, for low-grade serous ovarian cancer, launched earlier this year and has beaten consensus by approximately 100% for its partial and full quarters, with the core business expected to be self-sustaining in the next two to three quarters.
The company's G12D inhibitor program, licensed from GenFleet, has demonstrated strong clinical data with a 69% response rate as a single agent in G12D non-small cell lung cancer and a 58% response rate in second-line pancreatic cancer in Chinese studies, with a US Phase 1 study showing no dose-limiting toxicities and low GI toxicity.
Upcoming milestones include additional data in the first half of next year for the frontline metastatic pancreatic cancer study (avutometinib-defactinib plus Abraxane, which showed an 83% confirmed response rate in interim analysis) and for the US G12D inhibitor Phase 1 study, including combination data.

Nov 19, 2025, 2:30 PM

Transcript

Verastem Announces Public Offering of Common Stock and Pre-Funded Warrants

VSTM

Verastem, Inc. entered into an underwriting agreement on November 13, 2025, for a public offering of 8,543,794 shares of common stock and pre-funded warrants to purchase up to 3,870,000 shares of common stock.
The underwriters exercised their option in full on November 14, 2025, to purchase an additional 1,862,069 shares of common stock.
The public offering price for common stock is $7.25 per share, and for each pre-funded warrant is $7.2499.
Verastem expects to receive net proceeds of approximately $96.9 million from the offering, including the full exercise of the underwriters' option.
The closing of the offering is anticipated on or about November 17, 2025.

Nov 17, 2025, 12:30 PM

8-K

Verastem discusses LGSC commercial launch and RAMP 301 study updates

VSTM

Product Launch

Guidance Update

New Projects/Investments

Verastem reported strong sales in the third quarter for its commercial launch in LGSC, with over half of patients coming from large academic centers and a deliberate strategy to cover the market without needing more salespeople.
The company made a slight adjustment to patient enrollment in the confirmatory phase 3 RAMP 301 study for LGSC, adding 29 patients; final accrual is projected for Q1 2025, with PFS readout expected in the second half of 2027.
Verastem's KRAS G12D inhibitor, VS-7375, showed a 69% response rate in lung cancer and a 58% response rate in second-line pancreatic cancer in GenFleet's China trial, with Verastem's US trial aiming for equivalent efficacy with better tolerability.
The company is not yet providing revenue guidance for LGSC due to the early stage of the launch, but expects to do so once predictability improves, with Q4 2024 being the first full quarter with the complete distribution and support network.

Nov 11, 2025, 6:00 PM

Transcript

Verastem Oncology Reports Strong Q3 2025 Net Product Revenue and Commercial Launch Progress

VSTM

Earnings

Product Launch

Revenue Acceleration/Inflection

Verastem Oncology reported net product revenue of $11.2 million for the third quarter of 2025, marking its first full quarter of commercial launch for Avnaptifexinjacopac, which surpassed expectations.
For Q3 2025, the company recorded a non-GAAP adjusted net loss of $39.4 million, or $0.54 per share diluted.
Verastem ended Q3 2025 with $137.7 million in cash, cash equivalents, and investments, providing a cash runway into 2026.
The commercial launch of Avnaptifexinjacopac is progressing well, with 133 prescribers and payer coverage exceeding 80%.
Key clinical pipeline updates include the completion of enrollment for the RAMP-205 expansion cohort and a modest increase in enrollment for the RAMP-301 confirmatory Phase III trial, along with positive early safety data for the VS-7375 KRAS G12D inhibitor program.

Nov 4, 2025, 1:00 PM

Transcript

Earnings Transcripts

Quarterly earnings call transcripts for Verastem.

Ask Fintool AI Agent

Get instant answers from SEC filings, earnings calls & more

What did Daniel Paterson say about margins?What are Verastem's strategic priorities?How is Verastem positioned vs competitors?How did Verastem do last quarter?

Let Fintool AI Agent track Verastem's earnings for you

Get instant analysis when filings drop